Evidence map›Paper›PMID 38291896›Full record

ArticleRheumatology (Oxford, England)2025

Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: a population-based study.

Paras Karmacharya, Rikesh Chakradhar, Cassondra A Hulshizer, Tina M Gunderson, Alexis Ogdie, John M Davis Iii, Kerry Wright, Megha M Tollefson, Alí Duarte-García, Delamo Bekele and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Paras KarmacharyaDivision of Rheumatology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-1034-1530
Rikesh ChakradharDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Cassondra A HulshizerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Tina M GundersonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Alexis OgdieDepartments of Medicine/Rheumatology and Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-4639-0775
John M Davis IiiDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Kerry WrightDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Megha M TollefsonDepartments of Dermatology and Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Alí Duarte-GarcíaDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1749-5719
Delamo BekeleDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1907-0864
Hilal Maradit-KremersDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Cynthia S CrowsonDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5847-7475
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMetroHealth · USUniversity of Pennsylvania · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
HEART DISEASE IN RHEUMATOID ARTHRITISR01AR046849 · NIAMS · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2000 to 2022
$11.3M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
Association of Phenotypes and Genotype with Treatment Response in Psoriatic ArthritisK23AR082990 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paras Karmacharya · 2023 to 2026
$654k
CDC HHSCenter for the Science of Health Care DeliveryEaton Family Career DevelopmentGroup for Research and Assessment of Psoriasis and Psoriatic ArthritisNCATS NIH HHS UL1 TR002377NIAMS NIH HHS 1K23AR082990-01NIAMS NIH HHS K23 AR082990NIAMS NIH HHS R01 AR046849NIA NIH HHS R01 AG034676NIA NIH HHS R33 AG058738NIH HHSNIH HHS R01AG034676Rheumatology Research Foundation Scientist DevelopmentWomen's Health Career Enhancement
6 · The paper itself

Abstract

objectivesTo examine multimorbidity in psoriasis and its association with the development of psoriatic arthritis (PsA).

methodsA retrospective cohort study was performed using the Rochester Epidemiology Project. Population-based incidence (2000-09) and prevalence (1 January 2010) cohorts of psoriasis were identified by manual chart review. A cohort of individuals without psoriasis (comparators) were identified (1:1 matched on age, sex and county). Morbidities were defined using two or more Clinical Classification Software codes ≥30 days apart within prior 5 years. PsA was defined using ClASsification of Psoriatic ARthritis (CASPAR) criteria. χ2 and rank-sum tests were used to compare morbidities, and age-, sex- and race-adjusted Cox models to examine the association of baseline morbidities in psoriasis with development of PsA.

resultsAmong 817 incident psoriasis patients, the mean age was 45.2 years with 52.0% females, and 82.0% moderate/severe psoriasis. No multimorbidity differences were found between incident psoriasis patients and comparators. However, in the 1088 prevalent psoriasis patients, multimorbidity was significantly more common compared with 1086 comparators (odds ratio 1.35 and 1.48 for two or more and five or more morbidities, respectively). Over a median 13.3-year follow-up, 23 patients (cumulative incidence: 2.9% by 15 years) developed PsA. Multimorbidity (two or more morbidities) was associated with a 3-fold higher risk of developing PsA.

conclusionMultimorbidity was more common in the prevalent but not incident cohort of psoriasis compared with the general population, suggesting that patients with psoriasis may experience accelerated development of multimorbidity. Moreover, multimorbidity at psoriasis onset significantly increased the risk of developing PsA, highlighting the importance of monitoring multimorbid psoriasis patients for the development of PsA.

Indexed as

Arthritis, PsoriaticMultimorbidityPsoriasisAdultAgedComorbidityFemaleHumansIncidenceMaleMiddle AgedMinnesotaPrevalenceRetrospective StudiesRisk Factorscomorbidityepidemiologymultimorbiditypsoriasispsoriatic arthritisrisk factors

Identifiers

PMID38291896
PMCPMC11962958
OpenAlexW4391390102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.